12/3
08:00 am
urgn
UroGen Pharma Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Medium
Report
UroGen Pharma Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
11/19
05:08 am
urgn
UroGen Pharma Ltd. (
NASDAQ: URGN) was upgraded by analysts at Zacks Investment Research from a "sell" rating to a "hold" rating.
Medium
Report
UroGen Pharma Ltd. (
NASDAQ: URGN) was upgraded by analysts at Zacks Investment Research from a "sell" rating to a "hold" rating.
11/15
02:01 pm
urgn
UroGen Pharma Ltd. (URGN) CEO Liz Barrett on Q3 2021 Results - Earnings Call Transcript [Seeking Alpha]
Medium
Report
UroGen Pharma Ltd. (URGN) CEO Liz Barrett on Q3 2021 Results - Earnings Call Transcript [Seeking Alpha]
11/15
08:00 am
urgn
UroGen Pharma Reports Third Quarter 2021 Financial Results and Recent Corporate Developments
High
Report
UroGen Pharma Reports Third Quarter 2021 Financial Results and Recent Corporate Developments
11/11
08:00 am
urgn
UroGen Pharma Announces Upcoming 2021 Conferences
Low
Report
UroGen Pharma Announces Upcoming 2021 Conferences
11/10
11:00 am
urgn
UroGen Pharma Unveils New Phase 3 Development Plan for UGN-102 at Spotlight Event
Low
Report
UroGen Pharma Unveils New Phase 3 Development Plan for UGN-102 at Spotlight Event
11/1
08:00 am
urgn
UroGen Pharma to Host Virtual Spotlight Event on November 10, 2021
Low
Report
UroGen Pharma to Host Virtual Spotlight Event on November 10, 2021
10/7
03:26 pm
urgn
UroGen Pharma Ltd. (
NASDAQ: URGN) was downgraded by analysts at Zacks Investment Research from a "hold" rating to a "sell" rating.
Low
Report
UroGen Pharma Ltd. (
NASDAQ: URGN) was downgraded by analysts at Zacks Investment Research from a "hold" rating to a "sell" rating.
10/5
08:00 am
urgn
The Journal of Urology Publishes Results of UroGen Pharma’s Phase 2b Study of UGN-102 in Patients with Low-Grade Intermediate Risk Non-Muscle Invasive Bladder Cancer (LG IR-NMIBC)
Low
Report
The Journal of Urology Publishes Results of UroGen Pharma’s Phase 2b Study of UGN-102 in Patients with Low-Grade Intermediate Risk Non-Muscle Invasive Bladder Cancer (LG IR-NMIBC)
9/23
08:00 am
urgn
UroGen Pharma to Present at the 2021 Cantor Virtual Global Healthcare Conference
Low
Report
UroGen Pharma to Present at the 2021 Cantor Virtual Global Healthcare Conference
9/13
08:00 am
urgn
UroGen Pharma Presents Data Showcasing Novel Clinical Data at 2021 American Urological Association (AUA) Annual Meeting
Low
Report
UroGen Pharma Presents Data Showcasing Novel Clinical Data at 2021 American Urological Association (AUA) Annual Meeting
9/10
08:00 am
urgn
UroGen Pharma to Present at the H.C. Wainwright 23rd Annual Global Investment Conference
Low
Report
UroGen Pharma to Present at the H.C. Wainwright 23rd Annual Global Investment Conference